

RESEARCH ARTICLE

Open Access

A novel *COL4A1* gene mutation results in autosomal dominant non-syndromic congenital cataract in a Chinese family

Xin-Yi Xia^{1†}, Na Li^{1†}, Xiang Cao¹, Qiu-Yue Wu¹, Tian-Fu Li², Cui Zhang¹, Wei-Wei Li¹, Ying-Xia Cui¹, Xiao-Jun Li^{1*} and Chun-Yan Xue^{3*}

Abstract

Background: Almost one-third of congenital cataracts are primarily autosomal dominant disorders, which are also called autosomal dominant congenital cataract, resulting in blindness and clouding of the lens. The purpose of this study was to identify the disease-causing mutation in a Chinese family affected by bilateral, autosomal dominant congenital cataract.

Methods: The detection of candidate gene mutation and the linkage analysis of microsatellite markers were performed for the known candidate genes. Molecular mapping and cloning of candidate genes were used in all affected family members to screen for potential genetic mutations and the mutation was confirmed by single enzyme digestion.

Results: The proband was diagnosed with isolated, congenital cataract without the typical clinical manifestations of cataract, which include diabetes, porencephaly, sporadic intracerebral hemorrhage, and glomerulopathy. A novel mutation, c.2345 G > C (Gly782Ala), in exon 31 of the *collagen type IV alpha1 (COL4A1)* gene, which encodes the collagen alpha-1(IV) chain, was found to be associated with autosomal dominant congenital cataract in a Chinese family. This mutation was not found in unaffected family members or in 200 unrelated controls. Sequence analysis confirmed that the Gly782 amino acid residue is highly conserved.

Conclusions: The novel mutation (c.2345 G > C) of the *COL4A1* gene is the first report of a non-syndromic, autosomal dominant congenital cataract, thereby highlighting the important role of type IV collagen in the physiological and optical properties of the lens.

Keywords: Type IV collagen, COL4A1, Non-syndromic congenital cataract

Background

Almost one-third of congenital cataracts, also referred to as autosomal dominant congenital cataract (ADCC), are primarily autosomal dominant disorders that result in blindness and clouding of the lens. Such disorders account for 10% of all childhood blindness worldwide.

Additionally, there are a few reports of such disorders being inherited in an autosomal recessive or X-linked manner [1]. ADCC has highly variable morphologies (including total, polar, zonular, and capsular) within families and can include multisystem disorders, such as Wolf-Hirschhorn syndrome, SHORT syndrome, Abruzzo-Erickson syndrome [2], and HANAC syndrome [3]. The clinical manifestation of congenital cataract is multi-organs, including myopathy, cerebral hemorrhages, porencephaly, nephropathy, diabetes, etc. In general, non-syndromic, congenital cataracts that are not related to other disorders are rare, having an estimated frequency of 1–6 per 10,000 live births in industrialized countries, with one-third of cases having a positive family history [3,4] and

* Correspondence: lixiaojun1962@gmail.com; xuechunyan1973@gmail.com

[†]Equal contributors

¹Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, People's Republic of China

³Department of Ophthalmology, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, People's Republic of China

Full list of author information is available at the end of the article

5–15 per 10,000 live births in the poorest areas of the world [3,5]. To date, a series of congenital cataract-associated chromosomal locations have been mapped and over 30 genes have been identified by linkage analysis. Most of these genes include crystalline genes (*CRYAA*, *CRYAB*, *CRYBB1*, *CRYBB2*, *CRYBB3*, *CYRBA1*, *CRYBA3*, *CRYBA4*, *CRYGA*, *CRYGB*, *CRYGC*, *CRYGD*, and *CRYGS*) [6], membrane transport genes (*MIP*) [7], and gap junction proteins (*GJA3* and *GJA8*) [8]. The remaining known mutations are found in genes encoding growth and transcription factors, such as *HSF4*, *MAF*, *PITX3*, and *PAX6* [9]. However, it was discovered that *COL4A1* gene mutations were associated with ADCC in French families [10,11], and there were rare reports that the *type IV collagen, alpha1* (*COL4A1*) gene was associated with non-syndromic, autosomal dominant congenital cataract.

COL4A1 (NM_001845) and *COL4A2* (NM_001846) encode type IV collagen, which is present in almost all basement membranes and is highly conserved across species, and comprise 52 and 48 exons, respectively. They are arranged head-to-head on opposite strands of human chromosome 13. They are separated by 127 nucleotides containing a shared, bi-directional promoter that requires additional elements to control the tissue specificity and the level of protein expression [12]. Type IV collagen contains three major domains: an amino-terminal 7S domain, which participates in inter-molecular cross-linking and macromolecular organization, and a highly conserved, central triple-helix forming domain and a carboxyl-terminal, non-collagenous domain, which are globular domains responsible for the initiation of heterotrimer assembly [13].

It is known that humans carrying mutations in the *COL4A1* locus often exhibit lens abnormalities and cataracts, along with porencephaly, diabetes, sporadic

intracerebral hemorrhage and glomerulopathy [6]. However, a mutation of *COL4A1* gene resulting in isolated congenital cataract has never been reported previously.

Methods

Ethics statement

The Ethics Committee of Jinling Hospital approved the protocols used in this study. The research adhered to the tenets of the Declaration of Helsinki. All participants gave written consent to participate in the study, including consent to publish any accompanying images. Parental consent was obtained for children under the age of 16 years old.

Participant and clinical data

The large pedigree (Figure 1) of a five-generation Han family from a rural area in Jiangsu Province in China includes 15 affected and 64 unaffected individuals with typical features of congenital cataract. The proband (IV-7) came to our hospital for genetic counseling regarding cataract. All living members of this family underwent a systematic physical inspection and an examination that included slit-lamp microscopy of the lens and brain magnetic resonance imaging (MRI).

Detection of mutation of candidate genes and linkage analysis of microsatellite markers

Seventy-nine cases of the families were studied for linkage of the reported 17 candidate genes and 12 regions of chromosome with haplotypes associated with congenital cataracts using 27 microsatellite markers. However, all selected microsatellite markers were not linked with the reported disease genes and the LOD scores were not meaningful. This suggests that a novel gene mutation may result in congenital cataract.




Figure 1 The pedigree of a five-generation Chinese family with autosomal dominant congenital cataract is shown. The proband (IV-7) is indicated by a black arrow, and filled symbols indicate individuals with clinical manifestations of congenital cataract. All of the affected individuals carry the same *COL4A1* mutation.

Genome-wide genotyping for linkage analysis

A genome-wide linkage scan of the family was conducted to determine the chromosomal regions linked to congenital cataract. Seventy-nine family members (15 affected) participated in this study. DNA samples were genotyped using the Affymetrix GeneChip Human Mapping 500 K Array (Affymetrix, Santa Clara, CA, USA), which contains more than 500,000 SNPs. Array experiments were conducted according to the manufacturer's protocol. The Affymetrix GeneChip Operating Software (GCOS) was used for image processing. Genotypes were categorized with the Affymetrix Genotyping Console Software (GTC 4.0). Parametric, multipoint linkage analysis was performed using Merlin software under the assumption of autosomal-dominant inheritance with 99% penetrance, a disease allele frequency of 0.1%, and an equal SNP allele frequency (50%).

DNA sequencing analysis of the *COL4A1* and *COL4A2* genes and enzyme digestion detections

It was shown that six candidate genes, *LIG4*, *MYR8*, *ISR2*, *ING*, *COL4A1*, and *COL4A2*, might be associated with congenital cataracts. According to the instructions, all samples were stored at -20°C . The primers were designed using Primer 5 software based on the sequences of the 53 exons and 48 exons of the *COL4A1* and *COL4A2* genes, respectively, as well as their exon-intron boundaries. Polymerase chain reactions (PCRs) were performed under the following conditions: 95°C for 5 min followed by 35 cycles of 94°C for 30 s, 56°C - 60°C for 30 s, and 72°C for 60s, and the products were then sequenced. The sequencing results were compared to those in the NCBI Reference Sequence database. The PCR products from the *COL4A1* gene were detected by enzyme digestion with the endonuclease *PvuII*.

Results

Clinical findings

The proband (IV-7) came to our hospital for genetic counseling for congenital nuclear cataract, which resulted in blurred vision. The disc-shaped turbidity of the lens was located in the pupil area, as assessed using a slit-lamp (Figure 2A). Brain MRIs and renal function of the affected members were normal. A slit-lamp photograph taken of the proband indicated a normal cornea and iris, as well as the presence of a nuclear cataract (Figure 2B). There were no typical clinical manifestations of cataracts, which include diabetes, porencephaly, sporadic intracerebral hemorrhage, and glomerulopathy. Upon examination, the proband had a normal head posture, with a symmetrical facial appearance and normal dentition. It was further confirmed that the




Figure 2 The slit-lamp photograph of the dilated eye of the proband. (A) Slit-lamp photograph of the lens of the proband showing the nuclear cataract. All the affected individuals in the family have the same manifestations of nuclear cataract. (B) Photograph taken of the proband indicating a normal cornea and iris: a nuclear cataract was present.

congenital cataract of the family is an autosomal dominant disorder.

Linkage analysis

Twenty-seven microsatellite markers, according to genes that were previously shown to be associated with congenital cataracts, e.g. *CRYAA*, *CRYAB*, etc., were collected to conduct a linkage analysis of the susceptibility gene of the family. It was revealed that two-point LOD scores were less than minus 2. In other words, the susceptibility of the pedigree was not linked with the previously reported 19 candidate genes and 12 chromosome regions associated with ADCC. Thus, mutation of a novel gene resulted in the congenital cataract of this family.

Genome-wide genotyping for linkage analysis

Parametric, multipoint linkage analysis of the family revealed a genetic linkage region on chromosome 13q33.3-q33.4 (Figure 3). The genetic linkage region spanned approximately 3.3 Mb with a HLOD score of 5.413, and no significant linkage with markers on other




Figure 3 Parametric linkage analysis results for chromosome 13. The genetic linkage region spanned approximately 3.3 Mb with a HLOD score of 5.413 on chromosome 13q33.3-q33.4. No significant linkage with markers on other chromosomal regions was identified in the ADCC family.

chromosomal regions was identified in the ADCC family. Six candidate genes, *LIG6*, *MYR8*, *IRS2*, *COL4A1*, *COL4A2*, and *ING*, were located within the linkage region.

Mutational analysis of the *COL4A1* gene and enzyme digestion detections

It was reported that *COL4A1* or *COL4A2* mutations can cause ocular, cerebral, renal, and muscular defects [13]. Primers were designed to amplify the exons of *COL4A1* and *COL4A2* and PCRs were performed. The entire *COL4A1* gene was sequenced and a heterozygous G-to-C transition (c.2345 G > C) was identified in exon 31, leading to the replacement of a highly conserved glycine

residue by alanine at position 782 (Gly782Ala) within the triple-helix domain (Figure 4C). This mutation, which was not previously described, was not found in a panel of 200 control chromosomes of ethnically matched controls. The mutation was further confirmed by single enzyme digestion with the restriction endonuclease *PvuII* (Figure 4B).

Discussion

COL4 contain six known genes ($\alpha 1$ - $\alpha 6$). It was discovered that overexpression of *COL4A3* or *COL4A4* in the embryonic lens results in microphthalmia and cataract [14], and mutation in *COL4A3*, *COL4A3*, and *COL4A5* cause Alport syndrome [15]. The protein products of *COL4A1* and *COL4A2* are present in almostst all basements




Figure 4 Sequence analysis of exon 31 of the *COL4A1* gene and protein sequence alignments. **(A)** Identification of a *COL4A1* substitution mutation in a Chinese family. Directed sequence analysis of affected individuals revealed a substitution mutation (c.2345 G > C) in exon 31 of the *COL4A1* gene that was not found in 200 control patients. **(B)** Identification of the mutation (c.2345 G > C) carrier by single enzyme digestion with the restriction endonuclease *PvuII*. PCR product amplified from the uncleaved fragment is shown in the first lane and the second lane. **(C)** Protein sequence alignments of multiple species, *Homo sapiens*, *Bos taurus*, *Equus caballus* and *Mus musculus*, indicate a very strong degree of conservation of the amino acid altered by the mutation.

membranes of the extracellular matrix (ECM), whereas those of *COL4A3* through *COL4A6* are more spatially and temporally restricted. Congenital or early onset of cataract has previously been observed in patients with mutations in *COL4A1* [16,17], whereas congenital cataracts were always associated with multi-system disorders, along with cerebrovascular disease (brain small vessel disease and intracerebral hemorrhage), nephropathy, muscle cramps, and ocular anomalies. However, non-syndromic congenital cataracts, namely those not associated with other disorders are rare. Here, we discovered a Gly substitute mutation (c.2345 G > C) in exon 31 of the *COL4A1* gene that results in non-syndromic, autosomal dominant, congenital cataract. This mutation was predicted to have a deleterious effect on protein function by SIFT and Polyphen software (in Additional file 1).

The type IV collagens encoded by the paralogous genes *COL4A1* and *COL4A2* form heterotrimers in vivo: $\alpha1\alpha2\alpha3$ consists of long stretches of (Gly-X-Y)_n repeats, where X and Y are variable amino acids, with proline often occupying the Y position. There also exists an amino-terminal, 7S domain and a carboxyl-terminal, non-collagenous (NC1) domain. Gly in the triple helix domain is highly conserved across species, and mutation of this site may result in the destruction of the triple helix domain of the type IV collagens. Misfolded collagen proteins may, thus, disrupt the integrity of basement membranes in most parts of the eyes. In addition, they may also contribute to cataract development.

COL4A1 and *COL4A2* are translated at the rough endoplasmic reticulum (ER), where nascent peptides interact with ER resident proteins to ensure proper folding, post-translational modification, and heterotrimer assembly. The Gly substitution mutation of the *COL4A1* gene may result in the accumulation of unfolded, collagenous protein in the ER, and there were reports that this accumulation has been found to cause ER stress in some tissues, resulting in the subsequent activation of the unfolded protein response (UPR). The ER attempts to relieve stress in three ways. The first is to reduce the synthesis of related proteins, the second is to up-regulate the folding capacity of the ER, the last one is to increase the clearance of unfolded proteins [6]. If these mechanisms cannot alleviate the stress, the UPR pathway activates apoptosis. In conclusion, UPR activation in the lens secretory pathway might disrupt lens differentiation and cell survival, resulting in pathologies that lead to cataract formation. Until now, the precise pathologic mechanism resulting from *COL4A1* mutations in patients was poorly characterized and it was only presumed to impair protein secretion, thereby resulting in the intracellular accumulation of misfolded protein in the ER and the subsequent induction of the UPR pathway.

The tissue distribution and pathology severity depend on genetic and environmental factors, which commonly include cerebrovascular diseases, and ocular and renal defects. The *COL4A1* gene is the major element of basement membrane in the ECM and is distributed in all tissues. Mutations in *COL4A1* were first associated with cerebral microangiopathy and familial porencephaly [18]. Several authors have reported that mutations in *COL4A1* may be the Mendelian cause of prenatal onset intracranial hemorrhage [19]. The observed phenotypes are associated with generalized basement membrane (BM) defects, but show a high degree of tissue-specific variability. The non-syndromic, congenital cataract in our report is rare, and the pathological mechanism needs further intensive studies. In summary, our study reports, for the first time, that a *COL4A1* mutation is associated with autosomal dominant, congenital cataract in humans.

Conclusions

In this study, a novel mutation (c.2345 G > C) of *COL4A1* was detected in a Chinese family, and this mutation extends the mutational spectrum of ADCC. The molecular findings of non-syndromic ADCC resulting from the *COL4A1* mutation highlight the importance of analyzing type IV collagen genes (*COL4A1* and *COL4A2*) in congenital cataract patients.

Additional file

Additional file 1: Figure S1. The analysis result of SIFT Software.
Figure S2. The analysis result of Polyphen Software.

Abbreviations

ADCC: Autosomal dominant congenital cataract; COL4A1: Collagen, type IV, alpha1; CRYAA: Crystallin, alpha A; CRYAB: Crystallin, alpha B; CRYBB1: Crystallin, beta B1; CRYBB2: Crystallin, beta B2; CRYBB3: Crystallin, beta B3; CRYBA1: Crystallin, beta A1; CRYBA2: Crystallin, beta A2; CRYBA3: Crystallin, beta A3; CRYBA4: Crystallin, beta A4; CRYGA: Crystallin, gamma A; CRYGB: Crystallin, gamma B; CRYGC: Crystallin, gamma C; CRYGD: Crystallin, gamma D; CRYGS: Crystallin, gamma S; GJA3: Gap junction protein, alpha 3; GJA8: Gap junction protein, alpha 8; MIP: Major intrinsic protein of lens fiber; MAF: v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog; PITX3: Paired-like homeodomain 3; HSF4: Heat shock transcription factor 4; PAX6: Paired box 6; PCR: Polymerase chain reaction; COL4A1: Type IV collagen, alpha1; COL4A2: Type IV collagen, alpha2; COL4A3: Type IV collagen, alpha3; COL4A4: Type IV collagen, alpha4; COL4A5: Type IV collagen, alpha5; MRI: Magnetic resonance imaging; LIG4: Ligase IV; ECM: Extracellular matrix; NG1: Non-collagenous; ER: Endoplasmic reticulum; UPR: Unfolded protein response; BM: Basement membrane.

Competing interest

The authors declare that they have no competing interests.

Authors' contributions

CYX, XYX, NL conducted the experimental work. XYX, NL, XC, QYW, TFL, CZ and WWL analyzed the data. XYX, NL wrote the paper. XJL and YXC provided input for the paper. All authors read and approved the final manuscript.

Acknowledgment

This work was supported by the Natural Science Foundation of Jiangsu province (BK2011660) and Key Foundation of Jiangsu Science and Technology Bureau (BM2013058). We thank all members of the family for their cooperation in the study.

Author details

¹Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, People's Republic of China. ²Department of Neurology, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, People's Republic of China. ³Department of Ophthalmology, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, People's Republic of China.

Received: 4 May 2014 Accepted: 7 August 2014

Published: 15 August 2014

References

1. Hejtmancik JF: Congenital cataracts and their molecular genetics. *Semin Cell Dev Biol* 2008, **19**(2):134–149.
2. Rødahl E, Knappskog PM, Majewski J, Johansson S, Telstad W, Kråkenes J, Boman H: Variants of anterior segment dysgenesis and cerebral involvement in a large family with a novel COL4A1 mutation. *Am J Ophthalmol* 2013, **155**(5):946–953.
3. Apple D, Ram J, Foster A, Peng Q: Elimination of cataract blindness: a global perspective entering the new millennium. *Surv Ophthalmol* 2000, **45**:S1–S196.
4. Gilbert C, Foster A: Childhood blindness in the context of VISION 2020—the right to sight. *Bull World Health Organ* 2001, **79**(3):227–232.
5. Francis PJ, Berry V, Bhattacharya SS, Moore AT: The genetics of childhood cataract. *J Med Genet* 2000, **37**(7):481–488.
6. AlFadhli S, Abdelmoaty S, Al-Hajeri A, Behbehani A, Alkuraya F: Novel crystallin gamma B mutations in a Kuwaiti family with autosomal dominant congenital cataracts reveal genetic and clinical heterogeneity. *Mol Vis* 2012, **18**:2931–2936.
7. Berry V, Francis P, Kaushal S, Moore A, Bhattacharya S: Missense mutations in MIP underlie autosomal dominant polymorphic and lamellar cataracts linked to 12q. *Nat Genet* 2000, **25**(1):15–17.
8. Shiels A, Mackay D, Ionides A, Berry V, Moore A, Bhattacharya S: A missense mutation in the human Connexin50 Gene (GJA8) underlies autosomal dominant "zonular Pulverulent" cataract, on chromosome 1q. *Am J Hum Genet* 1998, **62**(3):526–532.
9. Jia X, Zhang F, Bai J, Gao L, Zhang X, Sun H, Sun D, Guan R, Sun W, Xu L, Yue Z, Yu Y, Fu S: Combinational analysis of linkage and exome sequencing identifies the causative mutation in a Chinese family with congenital cataract. *BMC Med Genet* 2013, **14**(1):107.
10. Sibon I, Coupry I, Menegon P, Bouchet J, Gorry P, Burgelin I, Calvas P, Orignac I, Douset V, Lacombe D, Orgogozo JM, Arveiler B, Goizet C: COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke. *Ann Neurol* 2007, **62**(2):177–184.
11. Coupry I, Sibon I, Mortemousque B, Rouanet F, Mine M, Goizet C: Ophthalmological features associated with COL4A1 mutations. *Arch Ophthalmol* 2010, **128**(4):483–489.
12. Haniel A, Welge-Lüssen U, Kühn K, Pöschl E: Identification and characterization of a novel transcriptional silencer in the human collagen type IV gene COL4A2. *J Biol Chem* 1995, **270**(19):11209–11215.
13. Kuo DS, Labelle-Dumais C, Gould DB: COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets. *Hum Mol Genet* 2012, **21**(R1):R97–R110.
14. Firtina Z, Danysh BP, Bai X, Gould DB, Kobayashi T, Duncan MK: Abnormal expression of collagen IV in lens activates unfolded protein response resulting in cataract. *J Biol Chem* 2009, **284**(51):35872–35884.
15. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG: Alport's syndrome, Goodpasture's syndrome, and type IV collagen. *N Engl J Med* 2003, **348**(25):2543–2556.
16. van der Knaap MS, Smit LM, Barkhof F, Pijnenburg YA, Zweegman S, Niessen HW, Imhof S, Heutink P: Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. *Ann Neurol* 2006, **59**(3):504–511.
17. Shah S, Kumar Y, McLean B, Churchill A, Stoodley N, Rankin J, Rizzu P, van der Knaap M, Jardine P: A dominantly inherited mutation in collagen IV A1

(COL4A1) causing childhood onset stroke without porencephaly. *Eur J Paediatr Neurol* 2010, **14**(2):182–187.

18. Gould DB, Phalan FC, Breedveld GJ, van Mil SE, Smith RS, Schimenti JC, Aguglia U, van der Knaap MS, Heutink P, John SW: Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. *Science* 2005, **308**(5725):1167–1171.
19. Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, Bousser MG, Heutink P, Miner JH, Tournier-Lasserre E, John SW: Role of COL4A1 in small-vessel disease and hemorrhagic stroke. *N Engl J Med* 2006, **354**(14):1489–1496.

doi:10.1186/s12881-014-0097-2

Cite this article as: Xia et al.: A novel COL4A1 gene mutation results in autosomal dominant non-syndromic congenital cataract in a Chinese family. *BMC Medical Genetics* 2014 **15**:97.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

